Brookline Capital Management Predicts CATX Q3 Earnings

Key Points

• Brookline Capital Management raised its Q3 2025 earnings per share estimate for Perspective Therapeutics from ($0.37) to ($0.36), while anticipating full-year earnings at ($0.88) per share.
• Analysts have mixed views on Perspective Therapeutics, with three analysts rating it as a Strong Buy, while others have set price targets ranging from $8.00 to $16.00.
• The stock of Perspective Therapeutics opened at $3.38 and has experienced a significant price fluctuation, with a 52-week low of $1.60 and a high of $16.55.

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Stock analysts at Brookline Capital Management raised their Q3 2025 EPS estimates for Perspective Therapeutics in a research report issued on Monday, August 18th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings per share of ($0.36) for the quarter, up from their previous estimate of ($0.37). The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Perspective Therapeutics' Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.33) EPS, Q1 2026 earnings at ($0.44) EPS, Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.57) EPS and FY2026 earnings at ($1.98) EPS.

CATX has been the subject of a number of other reports. B. Riley reaffirmed a "buy" rating and set a $12.00 price objective (up from $9.00) on shares of Perspective Therapeutics in a research report on Monday, June 23rd. Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Saturday, July 12th. Wedbush reaffirmed an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Monday, June 23rd. Royal Bank Of Canada raised shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and boosted their target price for the company from $15.00 to $16.00 in a research report on Tuesday, June 3rd. Finally, Truist Financial dropped their price target on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Perspective Therapeutics currently has an average rating of "Buy" and a consensus price target of $12.56.

Perspective Therapeutics Price Performance

Shares of NYSE:CATX traded up $0.12 during midday trading on Thursday, hitting $3.68. The stock had a trading volume of 579,561 shares, compared to its average volume of 940,145. Perspective Therapeutics has a 12 month low of $1.60 and a 12 month high of $16.55. The business's 50-day simple moving average is $3.79 and its 200-day simple moving average is $2.96.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CATX. ProShare Advisors LLC boosted its holdings in shares of Perspective Therapeutics by 49.1% during the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after buying an additional 5,011 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new position in shares of Perspective Therapeutics during the 4th quarter worth approximately $51,000. Ground Swell Capital LLC bought a new position in shares of Perspective Therapeutics during the 2nd quarter worth approximately $56,000. Corton Capital Inc. bought a new position in shares of Perspective Therapeutics in the 4th quarter worth $61,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Perspective Therapeutics in the 2nd quarter worth $61,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.